Compare VELO & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VELO | TNYA |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.2M | 153.2M |
| IPO Year | 2020 | 2021 |
| Metric | VELO | TNYA |
|---|---|---|
| Price | $3.03 | $0.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $19.50 | $3.67 |
| AVG Volume (30 Days) | 1.6M | ★ 2.5M |
| Earning Date | 11-10-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.96 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $45,973,000.00 | N/A |
| Revenue This Year | $61.07 | N/A |
| Revenue Next Year | $28.07 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.12 | N/A |
| 52 Week Low | $3.16 | $0.28 |
| 52 Week High | $31.75 | $1.46 |
| Indicator | VELO | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 25.68 | 28.74 |
| Support Level | N/A | N/A |
| Resistance Level | $11.94 | $0.42 |
| Average True Range (ATR) | 0.53 | 0.04 |
| MACD | -0.11 | 0.00 |
| Stochastic Oscillator | 0.57 | 11.92 |
Velo3D Inc provides additive manufacturing (AM), also referred to as three-dimensional printing (3D printing), to deliver breakthroughs in performance, cost, and time in the production of high-value metal parts. The Velo3D intelligent metal additive manufacturing solution is comprised of the Velo3D Flow intelligent print preparation software, the Sapphire production system, and Velo3D Assure, real-time quality assurance software. Its complete manufacturing solution enables clients to build the parts needed, speed their development, and reduce their product costs.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.